|
References
|
1
|
Klain M, Ricard M, Leboulleux S, Baudin E, Schlumberger M. Radioiodine therapy for papillary and follicular thyroid carcinoma. Eur J Nucl Med 2002, on line.
back to
|
|
2
|
Meier DA, Brill DR, Becker DV, Clarke SEM, Silberstein EB, Royal HD, Balon HR. Procedure guidelines for therapy of thyroid disease with 131Iodine. J Nucl Med 2002; 43: 856-861.
back to
|
|
3
|
Varma VM, Beierwaltes WH, Nofal MM, Nishiyama RH, Copp JE. Treatment of thyroid cancer: death rates after surgery and after surgery followed by sodium iodide I-131. JAMA 1970; 214:1437-1442.
back to
|
|
4
|
Creutzig H, Funke-Voelkers R, Kroenke C, Guth B, Henning A, Müller S. Risk factors in differentiated thyroid cancer. J Nucl Med 1987; 28: 527.
back to
|
|
5
|
Tubiana M. Thyroid cancer. In: Beckers C (ed) Thyroid diseases. Pergamon, Paris, 1982, pp 187-227.
back to
|
|
6
|
Van Tol KM, Hew JM, Jager PL, Vermey A, Dullart RP, Links TP. Embolizationin in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma. Clin Endocrinol 2000; 52:653-659.
back to
|
|
7
|
Hoefnagel CA. Metaiodobezylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med 1994; 21:1854-1857.
back to
|
|
8
|
Forssell-Aronson EB, Nilsson O, Benjegård SA et al. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptors subtypes in thyroid tumors. J Nucl Med 2000; 41:636-642.
back to
|
|
9
|
Waldeherr C, Schumacher T, Pless M, Crazzolara A, Maecke HR, Nitzsche EU et al. Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using [90 Y]-DOTA-D-Phe1 -Tyr3 -octreotide: a pilot study. Nucl Med Commun 2001; 22:673-678.
back to
|
|
10
|
Simon D, Koehrle J, Reiners C et al. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 1998; 22:569-574.
back to
|
|
11
|
De Kraker J, Hoefnagel CA, Caron HN, Valdés Olmos RA, Zsiros J, Hey HA, Voûte PA. First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma. Eur J Cancer 1995; 31A:600-602.
back to
|
|
12
|
Valdés Olmos, Hoefnagel CA, Bais E, Boot H, Taal B, de Kraker J, Voûte PA. Therapeutic advances of nuclear medicine in oncology. Rev Esp Med Nucl 2001; 20:547-557.
back to
|
|
13
|
Voûte PA, Hoefnagel CA, de Kraker J, Valdés Olmos RA, Bakker DJ, van de Kleij AJ. Results of treatment with [131I] -metaiodobenzylguanidine (131I -MIBG) in patients with neuroblastoma. Future prospects of zetotherapy. Prog Clin Biol Res 1991; 366:439-445.
back to
|
|
14
|
Voûte PA, van de Kleij AJ, de Kraker J, Hoefnagel CA, Tiel-van Buul MM, van Gennip H. Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV. Eur J Cancer 1995; 31A:5096-600.
back to
|
|
15
|
Gaze MN, Wheldon TE, Donoghue JA, et al. Multimodality megatherapy with [131I] -metaiodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: feasibility study of a new strategy for advanced neuroblastoma. Eur J Cancer 1995; 31A:252-256.
back to
|
|
16
|
Matthay KK, DeSantes K, Hasegawa B et al. Phase I dose escalation of [131I] -metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998; 16: 229-236.
back to
|
|
17
|
Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients J Endocrinol Invest 1997; 20:648-658.
back to
|
|
18
|
Chatal JF, Hoefnagel CA. Radionuclide therapy. Lancet 1999; 354: 931-935.
back to
|
|
19
|
Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikma J et al. Treatment of metastatic carcinoid tumors, phaechromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131I-meta-iodobenzylguanidine (131I-MIBG). Clin Endocrinol 2001; 55:47-60.
back to
|
|
20
|
Taal B, Hoefnagel CA, Valdés Olmos RA, Boot H, Beijnen JH. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 1996; 14:1829-1938.
back to
|
|
21
|
Taal BG, Hoefnagel CA, Boot H, Valdés Olmos RA, Rutgers M. Improved effect of 131I -MIBG treatment by predosing with non-radiolabelled MIBG in carcinoid patients, and studies in xenografted mice. Ann Oncol 2000; 11:1437-1443.
back to
|
|
22
|
Valkema R, de Jong M, Bakker WH, Breeman WAP, Kooij PPM, Lugtenburg PJ et al. Phase I study op peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The Rotterdam experience. Sem Nucl Med 2002;32;110-122.
back to
|
|
23
|
Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Sem Nucl Med 2002; 32:123-132.
back to
|
|
24
|
De Jong M, Kreening E. New advances in peptide receptor radionuclide therapy. J Nucl Med 2002; 43:617-620.
back to
|
|
25
|
Otte A, Herrmann R, Heppeler A, Behe M, Jermann, Powell P, Maecke HR, Muller J. Yttrium-90 DOTATOC: first clinicals results. Eur J Nucl Med 1999; 29:1439-1447.
back to
|
|
26
|
Paganelli G, Zoboli, Cremonesi M, et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe-Tyr3-octreotide. Eur J Nucl Med 2001; 28:426-434.
back to
|
|
27
|
De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkebom DJ, Breeman WAP et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Sem Nucl Med 2002; 32:133-140.
back to
|
|
28
|
Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. 111In- and 90Y-DOTA-lanreotide: results and implications of the Mauritius trial. Sem Nucl Med 2002; 32:148-155.
back to
|
|
29
|
Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000; 41:1704-1713.
back to
|
|
30
|
Hoefnagel CA, Clarke SEM, Fischer M, Chatal JF, Lewington VJ, Nilsson S, Troncone L, Viera MR. Radionuclide therapy practice and facilities in Europe. Eur J Nucl Med 1999; 26:277-282.
back to
|
|
|
